Biotech

Explore the landscape of Biotech in China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data and insights on Biotech to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Allist's Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive
CompanyDrug

Allist’s Firmonertinib Misses Primary PFS Endpoint in Phase 3 FURVENT Trial – 60% Response Rate and OS Trend Keep EGFR Exon 20 Insertion NSCLC Program Alive

Allist Pharmaceuticals Co., Ltd. (SHA: 688578) announced that the Phase 3 FURVENT trial (NCT05607550) evaluating firmonertinib monotherapy in previously untreated, locally advanced or metastatic non‑squamous NSCLC harboring EGFR exon 20…

anatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals Doses First Patient in Phase II Trial of DAT‑2645 – Novel Targeted Therapy for BRCA‑Mutant, HRD‑Positive Ovarian Cancer

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China's First PPARγ Inhibitor to Enter Clinical Development

Danatlas Pharmaceuticals Wins NMPA IND Approval for DAT‑6618 – China’s First PPARγ Inhibitor to Enter Clinical Development

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDeals

LaNova Medicines Secures Series B Funding to Advance Oncology Pipeline

CompanyDeals

Beijing Luzhu Biotechnology Secures Series C Funding for Meningococcal Vaccine Development

CompanyDrug

Recbio’s R520A mRNA COVID-19 Vaccine Receives Clinical Approval in the Philippines

Drug

Sinovac Biotech’s CoronaVac Receives Conditional Registration from South African Regulator

CompanyDrug

Sino Biopharmaceutical’s TQ-B3101 Accepted by NMPA for ROS1+ NSCLC Treatment

CompanyDrug

Ascletis Pharma Presents ASC22 Phase IIb Results for Chronic Hepatitis B at ILC 2022

CompanyDeals

Westlake Therapeutics Secures RMB 100 Million in Series A+ Funding for Red Cell Therapy Pipeline

CompanyDeals

Helixon Secures RMB 500 Million in Series A Round to Advance AI-Driven Drug Development

Show More